|
1. Ford HB, Schust DJ. Recurrent pregnancy loss: etiology, diagnosis, and therapy. Rev Obstet Gynecol 2009; 2(2): 76. 2. Nunes DP, Spegiorin LC, Mattos CC, Oliani AH, Vaz-Oliani DC, Mattos LC. The ADA* 2 allele of the adenosine deaminase gene (20q13. 11) and recurrent spontaneous abortions: an age-dependent association. Clin 2011; 66(11): 1929-33. 3. El Hachem H, Crepaux V, May-Panloup P, Descamps P, Legendre G, Bouet PE. Recurrent pregnancy loss: current perspectives. Int J Womens Health 2017; 9: 331. 4. Agarwal A, Gupta S, Sharma RK. Role of oxidative stress in female reproduction. Reprod Biol Endocrinol 2005; 3(1): 28. 5. Gulum M, Gumus K, Yeni E, Dogantekin E, Ciftci H, Akin Y, et al. Blood and semen paraoxonase—arylesterase activities in normozoospermic and azoospermic men. Androl 2017; 49(9): e12752. 6. Gil-Villa AM, Cardona-Maya W, Agarwal A, Sharma R, Cadavid Á. Role of male factor in early recurrent embryo loss: do antioxidants have any effect?. Fertil Steril 2009; 92(2): 565-71. 7. Kim DS, Marsillach J, Furlong CE, Jarvik GP. Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease. Pharmacogenomics 2013; 14(12): 1495-515. 8. Mackness M, Mackness B. Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles. Gene 2015; 567(1): 12-21. 9. Krzystek-Korpacka M, Boehm D, Matusiewicz M, Diakowska D, Grabowski K, Gamian A. Paraoxonase 1 (PON1) status in gastroesophageal malignancies and associated paraneoplastic syndromes—connection with inflammation. Clin Biochem. 2008; 41(10-11): 804-11. 10. Mackness MI, Durrington PN, Mackness B. The role of paraoxonase 1 activity in cardiovascular disease. Am J Cardiovasc Drugs 2004; 4(4): 211-7. 11. Dirican M, Akça R, Sarandol E, Dilek K. Serum paraoxonase activity in uremic predialysis and hemodialysis patients. J Nephrol 2004; 17(6): 813-8. 12. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21(4): 473-80. 13. Serhatlioglu S, Gursu MF, Gulcu F, Canatan H, Godekmerdan A. Levels of paraoxonase and arylesterase activities and malondialdehyde in workers exposed to ionizing radiation. Cell Biochem Funct 2003; 21(4): 371-5. 14. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 1999; 26(7-8): 892-904. 15. Camuzcuoglu H, Arioz DT, Toy H, Kurt S, Celik H, Erel O. Serum paraoxonase and arylesterase activities in patients with epithelial ovarian cancer. Gynecol Oncol 2009; 112(3): 481-5. 16. Jarvik GP, Tsai NT, McKinstry LA, Wani R, Brophy VH, Richter RJ, et al. Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler Thromb Vasc Biol 2002 1; 22(8): 1329-33. 17. Précourt LP, Amre D, Denis MC, Lavoie JC, Delvin E, Seidman E, et al., The three-gene paraoxonase family: physiologic roles, actions and regulation. Atheroscler 2011; 214(1): 20-36. 18. Solati M, Raiszadeh F, Azizi FE. Lipids, apolipoproteins, lipid oxidation and paraoxonase enzyme activity In diabetic and non-diabetic end stage renal disease patients. Int J Endocrinol Metab 2008; 4: 175-82. 19. Modaresi A, Nafar M, Sahraei Z. Oxidative stress in chronic kidney disease. Iran J Kidney Dis 2015; 9(3): 165. 20. Kural BV, Örem C, Uydu HA, Alver A, Örem A. The effects of lipid-lowering therapy on paraoxonase activities and their relationships with the oxidant–antioxidant system in patients with dyslipidemia. Coron Artery Dis 2004; 15(5): 277-83. 21. Ayar G, Atmaca YM, Alışık M, Erel Ö. Effects of paraoxonase, arylesterase, ceruloplasmin, catalase, and myeloperoxidase activities on prognosis in pediatric patients with sepsis. Clin Biochem 2017; 50(7-8): 414-7. 22. Gałczyński K, Bełtowski J, Nowakowski Ł, Vasilevska D, Rechberger T, Semczuk A. Serum paraoxonase 1 activity and protein N-homocysteinylation in primary human endometrial cancer. Tumour Biol 2018; 40(9): 1010428318797869.
|
